文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

患者使用不同干粉吸入器时的吸入特性。

The inhalation characteristics of patients when they use different dry powder inhalers.

作者信息

Azouz Wahida, Chetcuti Philip, Hosker Harold S R, Saralaya Dinesh, Stephenson John, Chrystyn Henry

机构信息

1 Department of Pharmacy, School of Applied Sciences, University of Huddersfield , Huddersfield, HD1 3DH, United Kingdom .

出版信息

J Aerosol Med Pulm Drug Deliv. 2015 Feb;28(1):35-42. doi: 10.1089/jamp.2013.1119. Epub 2014 May 9.


DOI:10.1089/jamp.2013.1119
PMID:24815999
Abstract

BACKGROUND: The characteristics of each inhalation maneuver when patients use dry powder inhalers (DPIs) are important, because they control the quality of the emitted dose. METHODS: We have measured the inhalation profiles of asthmatic children [CHILD; n=16, mean forced expiratory volume in 1 sec (FEV1) 79% predicted], asthmatic adults (ADULT; n=53, mean predicted FEV1 72%), and chronic obstructive pulmonary disease (COPD; n=29, mean predicted FEV1 42%) patients when they inhaled through an Aerolizer, Diskus, Turbuhaler, and Easyhaler using their "real-life" DPI inhalation technique. These are low-, medium-, medium/high-, and high-resistance DPIs, respectively. The inhalation flow against time was recorded to provide the peak inhalation flow (PIF; in L/min), the maximum pressure change (ΔP; in kPa), acceleration rates (ACCEL; in kPa/sec), time to maximum inhalation, the length of each inhalation (in sec), and the inhalation volume (IV; in liters) of each inhalation maneuver. RESULTS: PIF, ΔP, and ACCEL values were consistent with the order of the inhaler's resistance. For each device, the inhalation characteristics were in the order ADULT>COPD>CHILD for PIF, ΔP, and ACCEL (p<0.001). The results showed a large variability in inhalation characteristics and demonstrate the advantages of ΔP and ACCEL rather than PIFs. Overall inhaled volumes were low, and only one patient achieved an IV >4 L and ΔP >4 kPa. CONCLUSION: The large variability of these inhalation characteristics and their range highlights that if inhalation profiles were used with compendial in vitro dose emission measurements, then the results would provide useful information about the dose patients inhale during routine use. The inhalation characteristics highlight that adults with asthma have greater inspiratory capacity than patients with COPD, whereas children with asthma have the lowest. The significance of the inhaled volume to empty doses from each device requires investigation.

摘要

背景:患者使用干粉吸入器(DPI)时每次吸入动作的特征很重要,因为它们控制着喷出剂量的质量。 方法:我们测量了哮喘儿童[儿童组;n = 16,1秒用力呼气容积(FEV1)平均为预测值的79%]、哮喘成人(成人组;n = 53,FEV1平均预测值为72%)和慢性阻塞性肺疾病(COPD;n = 29,FEV1平均预测值为42%)患者使用其“实际生活中”的DPI吸入技术通过Aerolizer、Diskus、Turbuhaler和Easyhaler吸入时的吸入曲线。这些分别是低阻力、中阻力、中/高阻力和高阻力的DPI。记录吸气流量随时间的变化,以提供每次吸入动作的峰值吸气流量(PIF;单位为L/min)、最大压力变化(ΔP;单位为kPa)、加速度(ACCEL;单位为kPa/秒)、达到最大吸气的时间、每次吸入的时长(单位为秒)以及吸入容积(IV;单位为升)。 结果:PIF、ΔP和ACCEL值与吸入器阻力顺序一致。对于每种装置,PIF、ΔP和ACCEL的吸入特征顺序为成人组>COPD组>儿童组(p<0.001)。结果显示吸入特征存在很大变异性,并证明了ΔP和ACCEL而非PIF的优势。总体吸入容积较低,只有一名患者的IV>4 L且ΔP>4 kPa。 结论:这些吸入特征的巨大变异性及其范围突出表明,如果将吸入曲线与药典规定的体外剂量喷出测量相结合,那么结果将提供有关患者在常规使用期间吸入剂量的有用信息。吸入特征突出表明,哮喘成人的吸气能力大于COPD患者,而哮喘儿童的吸气能力最低。每种装置吸入容积对排空剂量的意义需要进行研究。

相似文献

[1]
The inhalation characteristics of patients when they use different dry powder inhalers.

J Aerosol Med Pulm Drug Deliv. 2015-2

[2]
Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.

J Aerosol Med Pulm Drug Deliv. 2015-12

[3]
Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.

Eur J Pharm Sci. 2019-8-28

[4]
Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.

BMC Pulm Med. 2015-5-1

[5]
[Peak inspiratory flow generated through different analogue dry powder inhalers in Shenzhen healthy preschool children].

Zhonghua Er Ke Za Zhi. 2008-2

[6]
[The variability of peak inspiratory flow (PIF) on valves imitating dry powder inhalers resistance during asthma and COPD exacerbations].

Pneumonol Alergol Pol. 2007

[7]
Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.

J Aerosol Med Pulm Drug Deliv. 2014-4

[8]
In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).

J Aerosol Med Pulm Drug Deliv. 2015-12

[9]
The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.

J Aerosol Med Pulm Drug Deliv. 2015-12

[10]
Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction.

J Aerosol Med. 2003

引用本文的文献

[1]
Technical evaluation of Turbuhaler use in children with bronchial asthma: combination of a checklist and inhalation parameters.

BMC Pulm Med. 2025-8-8

[2]
Use of a Digital Inhaler to Assess COPD Disease Variability and Identify Impending Acute COPD Exacerbations: A Pilot Study.

Chronic Obstr Pulm Dis. 2025-5-27

[3]
Dry-powder inhaler use in primary school-aged children with asthma: a systematic review.

ERJ Open Res. 2024-12-9

[4]
Scale-Up and Postapproval Changes in Orally Inhaled Drug Products: Scientific and Regulatory Considerations.

J Aerosol Med Pulm Drug Deliv. 2025-4

[5]
Small Airways Disease Affects Aerosol Deposition in Children with Severe Asthma: A Functional Respiratory Imaging Study.

J Aerosol Med Pulm Drug Deliv. 2024-12

[6]
Uncovering patterns of inhaler technique and reliever use: the value of objective, personalized data from a digital inhaler.

NPJ Prim Care Respir Med. 2024-8-20

[7]
Lipid polymer hybrid nanoparticles against lung cancer and their application as inhalable formulation.

Nanomedicine (Lond). 2024

[8]
Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System.

Pharmaceutics. 2024-1-10

[9]
Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis.

Pharmaceutics. 2023-5-13

[10]
Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development.

Pharmaceutics. 2022-11-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索